Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 6/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 6/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186819 | 0.98 | CYP2C19 (0.44) | TBXAS1CYP2C19CYP4F2CYP4A11FFAR4 | |
| SCHEMBL14106427 | 0.95 | TBXAS1 (0.41) | TBXAS1CYP2C19CYP4F2CYP4A11FFAR4 | |
| SCHEMBL187698 | 0.94 | TBXAS1 (0.40) | TBXAS1CYP2C19CYP4F2CYP4A11FFAR4 | |
| SCHEMBL186576 | 0.92 | FFAR4 (0.40) | TBXAS1CYP4F2CYP4A11FFAR4ACACB | |
| SCHEMBL18633532 | 0.91 | FFAR4 (0.39) | TBXAS1CYP4F2CYP4A11FFAR4ACACB | |
| SCHEMBL186552 | 0.90 | FFAR4 (0.37) | TBXAS1CYP2C19CYP4F2CYP4A11FFAR4 | |
| SCHEMBL798202 | 0.86 | TBXAS1 (0.54) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL9182194 | 0.86 | TBXAS1 (0.54) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL17764132 | 0.85 | TBXAS1 (0.36) | TBXAS1CYP2C19CYP4F2CYP4A11FFAR4 | |
| SCHEMBL17099445 | 0.84 | FFAR1 (0.54) | FFAR4FFAR1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3421447-B1 | FATTY ACID COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-03-24 | — | — | EP | disclosed |
| EP-3421447-B1 | FATTY ACID COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-03-24 | — | — | EP | disclosed |
| US-20200189999-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200189999-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2020-06-18 | — | — | US | disclosed |
| US-10414713-B2 | Fatty acid compound, preparation method therefor and use therefor | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-09-17 | — | — | US | disclosed |
| US-10414713-B2 | Fatty acid compound, preparation method therefor and use therefor | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-09-17 | — | — | US | disclosed |
| US-20190084908-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190084908-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190039989-A1 | FATTY ACID COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREFOR | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-02-07 | — | — | US | disclosed |
| US-20190039989-A1 | FATTY ACID COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREFOR | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-02-07 | — | — | US | disclosed |
| US-8067466-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management | ESPERION THERAPEUTICS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20080249166-A1 | Inhibiting hepatic fatty acid and sterol synthesis; use with statins; compounds such as cyclopropyl or cyclobutyl-functional hydroxy-functional alpha,gamma-alkanediacids | ESPERION THERAPEUTICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249166-A1 | Inhibiting hepatic fatty acid and sterol synthesis; use with statins; compounds such as cyclopropyl or cyclobutyl-functional hydroxy-functional alpha,gamma-alkanediacids | ESPERION THERAPEUTICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249166-A1 | Inhibiting hepatic fatty acid and sterol synthesis; use with statins; compounds such as cyclopropyl or cyclobutyl-functional hydroxy-functional alpha,gamma-alkanediacids | ESPERION THERAPEUTICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-7405226-B2 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | PFIZER INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405226-B2 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | PFIZER INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405226-B2 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | PFIZER INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20060229281-A1 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | ESPERION THERAPEUTIC, INC. | 2006-10-12 | — | — | US | disclosed |
| US-7119221-B2 | treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders | ESPERION THERAPEUTICS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20040209847-A1 | treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders | ESPERION THERAPEUTICS, INC. | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190039989-A1 | FATTY ACID COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREFOR | FAR1, HADH, FFAR4 | TBXAS1 828/4885CYP2C19 2060/4885CYP4F2 208/4885 |
| US-10414713-B2 | Fatty acid compound, preparation method therefor and use therefor | FAR1, HADH, FFAR4 | TBXAS1 828/4885CYP2C19 2060/4885CYP4F2 208/4885 |
| US-20190084908-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | TBXAS1 456/4885CYP2C19 1033/4885CYP4F2 2014/4885 |
| US-20040209847-A1 | treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders | PNLIP, APOL1, NR1H3 | TBXAS1 418/4885CYP2C19 1278/4885CYP4F2 2326/4885 |
| US-20200189999-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | TBXAS1 456/4885CYP2C19 1033/4885CYP4F2 2014/4885 |
| US-20080249166-A1 | Inhibiting hepatic fatty acid and sterol synthesis; use with statins; compounds such as cyclopropyl or cyclobutyl-functional hydroxy-functional alpha,gamma-alkanediacids | PNLIP, NR1H3, NR1H2 | TBXAS1 346/4885CYP2C19 600/4885CYP4F2 713/4885 |
| US-20060229281-A1 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | PNLIP, CYP27A1, GPR119 | TBXAS1 301/4885CYP2C19 1035/4885CYP4F2 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.